Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition.
Proteau S, Krossa I, Husser C, Guéguinou M, Sella F, Bille K, Irondelle M, Dalmasso M, Barouillet T, Cheli Y, Pisibon C, Arrighi N, Nahon-Estève S, Martel A, Gastaud L, Lassalle S, Mignen O, Brest P, Mazure NM, Bost F, Baillif S, Landreville S, Turcotte S, Hasson D, Carcamo S, Vandier C, Bernstein E, Yvan-Charvet L, Levesque MP, Ballotti R, Bertolotto C, Strub T. Proteau S, et al. Among authors: sella f. EMBO Mol Med. 2023 Dec 7;15(12):e17719. doi: 10.15252/emmm.202317719. Epub 2023 Nov 15. EMBO Mol Med. 2023. PMID: 37966164 Free PMC article.
Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma.
Ferretti LP, Böhi F, Leslie Pedrioli DM, Cheng PF, Ferrari E, Baumgaertner P, Alvarado-Diaz A, Sella F, Cereghetti A, Turko P, Wright RH, De Bock K, Speiser DE, Ferrari R, Levesque MP, Hottiger MO. Ferretti LP, et al. Among authors: sella f. Cancer Res. 2023 Dec 1;83(23):3974-3988. doi: 10.1158/0008-5472.CAN-23-0485. Cancer Res. 2023. PMID: 37729428
Publisher Correction: LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition.
Proteau S, Krossa I, Husser C, Guéguinou M, Sella F, Bille K, Irondelle M, Dalmasso M, Barouillet T, Cheli Y, Pisibon C, Arrighi N, Nahon-Estève S, Martel A, Gastaud L, Lassalle S, Mignen O, Brest P, Mazure NM, Bost F, Baillif S, Landreville S, Turcotte S, Hasson D, Carcamo S, Vandier C, Bernstein E, Yvan-Charvet L, Levesque MP, Ballotti R, Bertolotto C, Strub T. Proteau S, et al. Among authors: sella f. EMBO Mol Med. 2024 Sep;16(9):2262-2267. doi: 10.1038/s44321-024-00114-1. EMBO Mol Med. 2024. PMID: 39164473 Free PMC article.
COL10A1 expression distinguishes a subset of cancer-associated fibroblasts present in the stroma of high-risk basal cell carcinoma.
Esposito M, Yerly L, Shukla P, Hermes V, Sella F, Balazs Z, Lattmann E, Tastanova A, Turko P, Lang R, Kolm I, Staeger R, Kuonen F, Krauthammer M, Hafner J, Levesque MP, Restivo G. Esposito M, et al. Among authors: sella f. Br J Dermatol. 2024 Oct 17;191(5):775-790. doi: 10.1093/bjd/ljae258. Br J Dermatol. 2024. PMID: 38916477
Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance.
Vasilevska J, Cheng PF, Lehmann J, Ramelyte E, Gómez JM, Dimitriou F, Sella F; TuPro Consortium; Ferretti D, Salas-Bastos A, Jordaan WS, Levesque MP, Dummer R, Sommer L. Vasilevska J, et al. Among authors: sella f. Cell Rep Med. 2024 Jul 16;5(7):101611. doi: 10.1016/j.xcrm.2024.101611. Epub 2024 Jun 27. Cell Rep Med. 2024. PMID: 38942020 Free PMC article.
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma.
Dimitriou F, Cheng PF, Saltari A, Schaper-Gerhardt K, Staeger R, Haunerdinger V, Sella F, Tastanova A, Urban C, Dettwiler S, Mihic-Probst D, Matter CM, Michielin O, Gutzmer R, Long GV, Becher B, Levesque MP, Dummer R. Dimitriou F, et al. Among authors: sella f. Nat Cancer. 2024 Sep;5(9):1390-1408. doi: 10.1038/s43018-024-00810-4. Epub 2024 Aug 29. Nat Cancer. 2024. PMID: 39210005 Free PMC article.
Temporal genomic analysis of homogeneous tumor models reveals key regulators of immune evasion in melanoma.
Cohen Shvefel S, Pai JA, Cao Y, Pal LR, Bartok O, Levy R, Zemanek MJ, Weller C, Herzog E, Yao W, Hiam-Galvez KJ, Cheng K, Yin Y, Du PP, Raposo CJ, Gumpert N, Welti M, Martínez Gómez JM, Sella F, Yakubovich E, Orr I, Ben-Dor S, Oren R, Fellus-Alyagor L, Golani O, Brenner OJ, Salame TM, Zerbib M, Goliand I, Ranmar D, Savchenko I, Ketrarou N, Schaffer AA, Dahan R, Levesque MP, Ruppin E, Satpathy AT, Samuels Y. Cohen Shvefel S, et al. Among authors: sella f. Cancer Discov. 2024 Nov 20. doi: 10.1158/2159-8290.CD-23-1422. Online ahead of print. Cancer Discov. 2024. PMID: 39715301
Endocannabinoid System and Metabolism: The Influences of Sex.
Forner-Piquer I, Giommi C, Sella F, Lombó M, Montik N, Dalla Valle L, Carnevali O. Forner-Piquer I, et al. Among authors: sella f. Int J Mol Sci. 2024 Nov 6;25(22):11909. doi: 10.3390/ijms252211909. Int J Mol Sci. 2024. PMID: 39595979 Free PMC article. Review.
72 results